Podcasts and other audio content from Phil Dobbie

Astra Zeneca re-run, Lane’s credit concerns

A soggy day on the markets says NAB’s David de Garis, but the continue rise in base metals points to the growth in China, whilst the rest of the world struggles with the virus.

Ask Steve: Keynesian v Post Keynesian; Austrian v Chicago Schools

The Austrian School v the Chicago School v Keynesian economics v Post-Keynesianism. The differences explained on today’s Debunking Economics podcast with @profstevekeen

Not much to be thankful for

FOMC minutes confirm they are looking at buying at longer end of curve. NAB’s Ray Attrill say that this will perhaps happen sooner than expected.

Trump relents, oil climbs and Dow hits new high

Trump is ready to give the keys to the White House. NAB’s Rodrigo Catril says the news has given the market some positivity, along with Janet Yellen set to become Treasury Secretary in the US, together with more vaccine hopes.

More positive vaccine news, but equities are cautious

More vaccine news today, this time from Astra Zeneca. NAB’s David de Garis says we’re seeing the return of hotels and airlines stocks at the expense of the tech sector, whilst the US dollar has been helped by better than expected Markit PMIs.

Revised Aussie Growth Forecast and a Fed-Treasury Spat

Australia’s 2021 growth forecast has been revised. NAB’s Tapas Strickland talks through the good news, plus the spat between the US Fed and the Treasury.

Lockdown jitters

The ferocity of the virus numbers of the US is seeing markets taking a more pessimistic short term view, despite positive vaccine news, says NAB’s Gavin Friend.

Lockdowns and infections overshadow further positive vaccine news

Pfizer is days away from submitted their vaccine for FDA approval. The markets haven’t been excited by the news. NAB’s David de Garis says rising COVID numbers have overshadowed the response.

Markets take a breather, but standby for more vaccine news

Markets take a breather for now, but NAB’s Tapas Strickland says news from the Oxford vaccine trial are imminent and we could see a repeat of the reaction to the first two bits of trial news.

And another one

It’s all about the vaccine, says NAB’s Rodrigo Catril, as Moderna announces successful trials, with the markets ignoring the likely economic hit for Q3 and Q4.

Scroll to top